Roivant Sciences(US:ROIV) Globenewswire·2025-10-27 20:10Core Viewpoint - Roivant is set to host a live conference call on November 10, 2025, to report its financial results for Q2 2025 and provide a business update [1]. Company Overview - Roivant is a biopharmaceutical company focused on accelerating the development and commercialization of impactful medicines [3]. - The company's pipeline includes several key product candidates: - Brepocitinib, a small molecule inhibitor of TYK2 and JAK1 for treating dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis [3]. - IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn for various IgG-mediated autoimmune conditions [3]. - Mosliciguat, an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease [3]. - Roivant employs a strategy of creating nimble subsidiaries, referred to as "Vants," to develop and commercialize its medicines and technologies [3]. - In addition to therapeutics, Roivant also incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business [3].